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Abstract
Background: To evaluate the effect of Recurrence Score® results (RS; Oncotype DX® multigene assay ODX) on
treatment recommendations by Swiss multidisciplinary tumor boards (TB).
Methods: SAKK 26/10 is a multicenter, prospective cohort study of early breast cancer patients: Eligibility: R0-resection,
≥10% ER+ malignant cells, HER2–, pN0/pN1a. Patients were stratified into low-risk (LR) and non-low-risk (NLR) groups
based on involved nodes (0 vs 1–3) and five additional predefined risk factors. Recommendations were classified as
hormonal therapy (HT) or chemotherapy plus HT (CT + HT). Investigators were blinded to the statistical analysis plan.
A 5%/10% rate of recommendation change in LR/NLR groups, respectively, was assumed independently of RS
(null hypotheses).
Results: Two hundred twenty two evaluable patients from 18 centers had TB recommendations before and after
consideration of the RS result. A recommendation change occurred in 45 patients (23/154 (15%, 95% CI 10–22%) in the
LR group and 22/68 (32%, 95% CI 22–45%) in the NLR group). In both groups the null hypothesis could be rejected (both
p < 0.001). Specifically, in the LR group, only 5/113 (4%, 95% CI 1–10%) with HT had a recommendation change to
CT + HT after consideration of the RS, while 18/41 (44%, 95% CI 28–60%) of patients initially recommended CT + HT were
subsequently recommended only HT. In the NLR group, 3/19 (16%, 95% CI 3–40%) patients were changed from HT to
CT + HT, while 19/48 (40%, 95% CI 26–55%) were changed from CT + HT to HT.
Conclusion: There was a significant impact of using the RS in the LR and the NLR group but only 4% of LR patients
initially considered for HT had a recommendation change (RC); therefore these patients could forgo ODX testing. A RC
was more likely for NLR patients considered for HT. Patients considered for HT + CT have the highest likelihood of a RC
based on RS.
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Background
While initial trials in unselected women with early-stage
ER-positive breast cancer failed to demonstrate a beneficial
effect from adding chemotherapy to adjuvant endocrine
therapy [1–4], it later became apparent that adjuvant
chemo-endocrine therapy does reduce the recurrence rate
compared with adjuvant endocrine therapy alone in certain
selected populations. One approach to identifying which
patients should receive adjuvant CT in addition to adju-
vant endocrine therapy was described in the St. Gallen
Consensus Highlights in 2009 [5]. The following factors
can be used to separate patients with lower and higher
risk of relapse and death: Nodal status, primary tumor
size, ER/PgR level, histologic tumor grade, proliferation
fraction (Ki67), lymphovascular invasion. In addition, the
NSABP B-20 [6] and SWOG 8814 [7] trials demonstrated
that gene expression profiling is a useful tool for selecting
patients who are most likely to benefit from adding
chemotherapy to adjuvant treatment in patients with
node-negative and node-positive breast cancers, respect-
ively. In both these trials, patients were stratified into
three distinct groups following measurement of RNA ex-
pression using the ODX assay developed by Genomic
Health Incorporated (GHI). The ODX assay is a multigene
reverse-transcriptase polymerase chain reaction (RT-PCR)
test that analyzes the expression of 21 genes and estimates
the 10-year distant breast cancer recurrence risk. The
assay was validated in the NSABP B-14 trial, a large, mul-
ticenter trial for women with node-negative, ER-positive
breast cancer treated with tamoxifen [8]. The ODX assay
result Recurrence Score (RS) provides as a continuous
variable ranging from 0 to 100. For statistical analysis, pa-
tients are typically grouped into three risk categories based
on the RS: low (RS 0–17), intermediate (RS 18–30), and
high (RS ≥31). These categories have been shown to correl-
ate with the rate of distant recurrence in multiple studies in
node negative [8–11] and node positive disease [7, 12] at
10 years as well as overall survival [8].
The NSABP B-20 trial showed that the benefit of adding
chemotherapy (cyclophosphamide, methotrexate, fluoro-
uracil) to tamoxifen was mainly seen in a relatively small
group of patients with a high RS (≥31) [6]. These patients
had an absolute decrease in 10-year distant recurrence rate
of 28% with adjuvant chemotherapy plus endocrine therapy
compared with adjuvant endocrine therapy alone. Patients
in the low and intermediate RS risk groups had no signifi-
cant benefit from the addition of chemotherapy [6]. Simi-
larly, in the SWOG 8814 (INT0100) trial performed in
patients with node-positive breast cancer the benefit of
adding cyclophosphamide, doxorubicin, and fluorouracil
followed by tamoxifen compared with tamoxifen alone was
seen only in patients with high RS [7].
The ODX assay has been available in the US since 2004
as a tool to aid a physician’s treatment recommendation for
patients with early breast cancer and was recommended by
an ASCO expert panel for use in patients with ER-positive
early breast cancer in 2007 [13]. TAILORx, a prospective
clinical trial, confirmed that patients with node negative
breast cancer and a low RS (<11) had a very low risk of dis-
tant relapse [11].
Several studies have attempted to analyze the contribu-
tion of ODX assay to decisions on adjuvant treatment in
patients with ER-positive breast cancer. In an American
study of 89 patients with node-negative disease, the assay
led to changes in treatment decisions in 31% of cases [14],
although whether design of this study allowed these
decision changes to be attributed to the use of the ODX
assay was later questioned [15]. Since then, similar studies
in Australia [16], Canada [17], Germany [18], France [19],
Israel [20], Japan [21], Spain [22], and the United Kingdom
[23] have consistently shown that knowledge of the ODX
RS changed treatment plans in about 30% of cases. The
majority of changed decisions were due to “de-escalation”
from chemotherapy plus endocrine therapy to endocrine
therapy alone.
In Switzerland, the ODX assay was not reimbursed until
2015 and was rarely performed. In contrast, Swiss oncolo-
gists often used the Ki-67 proliferation assay, expression
levels of estrogen and/or progesterone receptor, histological
grading and nodal status to support a recommendation for
or against adjuvant chemotherapy [24, 25].We studied
whether the introduction of the ODX assay impacted on
treatment recommendations issued by Swiss multidisciplin-
ary tumor boards.
Methods
Patient population
SAKK 26/10 (NCT01926964) is a multicenter, pro-
spective cohort study. Participants had completely
resected breast cancer with pathologically confirmed
negative margins. Participants also had to have ≥10%
ER-positive invasive malignant cells, HER2-negative
carcinoma by immunohistochemistry (0 or 1+) or by
FISH (ratio of HER2/Cen17 ≤ 2.0) by local pathology,
and a regional lymph node status of pN0 or pN1a
(1–3 positive nodes) as determined by axillary dissec-
tion or sentinel procedure [26, 27].
Each case was presented at the center’s multidisciplinary
tumor board where a first recommendation on adjuvant
systemic treatment was issued. The following items were
required for baseline data collection (“pre-registration”
step): pathologic maximum tumor diameter (in mm), per-
centage of ER-positive and progesterone (PgR)-positive in-
vasive tumor cells, Ki-67 proliferation rate (MIB-1
antibody), and the modified Bloom-Richardson-Elston
(BRE) grade. In addition, for study eligibility (“registration”
step), the patient had to be considered suitable to receive
adjuvant chemotherapy, have a WHO performance status
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0–1, and have sufficient invasive breast cancer tissue avail-
able to prepare 39 tissue sections (thickness 5 μm). Patients
with bilateral invasive breast cancer and those with tumors
of stage cT4, pT4 or pN ≥ 2 or known metastatic breast
cancer were excluded, as were pregnant women and pa-
tients with psychiatric or medical diagnoses potentially
interfering with their ability to give informed consent.
Study procedures
The treating physician then invited the patient to partici-
pate in the study, explaining in the discussion the uncer-
tainty surrounding the use of adjuvant chemotherapy in
addition to the adjuvant endocrine therapy, and issuing the
recommendation of the first tumor board discussion. If the
patient agreed to participate in the study, the result of this
first discussion was recorded as the “first shared decision”.
Only after this, breast cancer tissue was sent to Genomic
Health Inc. where the ODX RS was determined and
returned usually within 7 working days after receipt of the
samples. The patient case was then re-presented at the
tumor board along with the RS, and a second tumor board
recommendation was issued. The RS result and the second
tumor board recommendation were then discussed with
the patient, and the result of this “second shared decision”
was recorded. The “treatment actually given” after the initi-
ation of adjuvant systemic treatment was also recorded. All
recommendations (i.e. first tumor board recommendation,
first shared decision, second tumor board recommendation,
second shared decision) as well as the treatment actually
given were classified as either hormonal therapy (HT) or
chemotherapy plus endocrine therapy (CT + HT).
The primary endpoint of the study was the percentage of
treatment decisions that changed between the first and sec-
ond tumor board recommendations (after the inclusion of
the RS). Importantly, the investigators contributing patients
to the study were blinded to the statistical analysis plan.
The protocol also stratified the patients into two risk
groups based on involved nodes (0 versus 1–3) and other
predefined risk factors taken from the St. Gallen consensus
guidelines [5, 29]. These risk factors were: ER-positivity
<50% and PgR-positivity <50%, grade 3, tumor size >5 cm,
extensive lympho-vascular invasion, and Ki67 > 30%.
Patients were deemed to be at low risk of recurrence if they
had pN0 tumor and ≤1 risk factor present or pN1a with no
other risk factor. Patients were non-low risk if they had
pN0 tumor plus ≥2 risk factors, or if pN1a plus ≥1 other
risk factor. This risk stratification was held concealed from
the participating investigators.
Statistical analyses
The null hypothesis was that there would be a 5% change
of recommendation in the low-risk group, and a 10%
change of recommendation in the non-low-risk groups,
following the second tumor board recommendation. These
levels of change were expected to occur independently of
the RS. The alternative hypothesis was that a change of rec-
ommendation after consideration of the RS would occur in
at least 15% in the low-risk group, and of at least 25% in
the non-low-risk group. These levels of change were set a
priori to be considered clinically interesting and relevant.
Using these hypotheses and the exact binomial test, assum-
ing a one-sided type I error of 0.025, a power of 90%, and
an expected proportion of non-evaluable patients of 10%,
the required sample size was 175 patients in total (93 pa-
tients in the low-risk group, 64 patients in the non-low-risk
group). When the low-risk group had attained its accrual
goal it was decided to continue accrual into both groups in
order to keep up the blinding of investigators concerning
the concealed statistical analysis plan. The study was closed
only when the non-low-risk group was complete.
Point estimates and the corresponding exact 95% confi-
dence interval were calculated for proportions. Spearman’s
rank correlation coefficient together with the 95% confi-
dence interval was calculated for the comparison of scores,
while the kappa coefficient with the 95% confidence inter-
val was calculated to compare categorized scores. SAS 9.2
and R 3.1.0 were used for the statistical analyses.
Results
Between July 2013 and June 2014 we recruited 229
eligible patients at 18 study sites in Switzerland. Of
these, 222 patients were evaluable and 221 patients
had a recommendation from both the first and
second tumor board and had an ODX RS available
(Fig. 1): 154 patients in the low-risk group and 67
patients in the non-low-risk group.
Non-lowLow
Informed consent
Baseline data 174 70
Not eligible for participation: 12
Investigator’s decision: 1
Patient’s decision: 1
Not eligible for participation: 1
Study participation,
1st tumor board 
recommendation
160 69
2nd tumor board 
recommendation
(Primary endpoint)
154 67
Patient retraction: 1
Evaluable for 
analysis 154 68
244Pre-registered
No RS obtained: 6
No RS obtained: 1
Fig. 1 Patient Flow
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Table 1 Patient characteristics
Variable Low-risk group (N = 160) Non-low-risk group (N = 69) Total (N = 229)
Age, median (range) 58 (35–82) 58 (32–79) 58 (32–82)
Menopausal status, n (%)
Premenopausal 41 (26%) 23 (33%) 64 (28%)
Peri-menopausal 5 (3%) 5 (7%) 10 (4%)
Postmenopausal 114 (71%) 41 (59%) 155 (68%)
pT stage, n (%)
T1 2 (1%) 2 (3%) 4 (2%)
T1a 2 (1%) - 2 (1%)
T1b 19 (12%) 5 (7%) 24 (10%)
T1c 75 (47%) 33 (48%) 108 (47%)
T2 57 (36%) 23 (33%) 80 (35%)
T3 4 (3%) 6 (9%) 10 (4%)
Tis 1 (1%) - 1 (0%)
pN stage, n (%)
pN0 122 (76%) 19 (28%) 141 (62%)
pN1a 38 (24%) 50 (72%) 88 (38%)
Histologic type, n (%)
Invasive ductal carcinoma 119 (74%) 56 (81%) 175 (76%)
Invasive lobular carcinoma 31 (19%) 9 (13%) 40 (17%)
Other 10 (6%) 4 (6%) 14 (6%)
Tumor grade (BRE), n (%)
G 1 24 (15%) 5 (7%) 29 (13%)
G 2 124 (78%) 27 (39%) 151 (66%)
G 3 12 (8%) 37 (54%) 49 (21%)
Peritumoral lympho-vascular invasion, n (%)
No 153 (96%) 25 (36%) 178 (78%)
Yes 7 (4%) 44 (64%) 51 (22%)
Table 2 Distribution of predefined risk factors in the low- and non-low-risk groups (all evaluable patients)
Variable Low-risk groupa (N = 154) Non-low-risk groupa (N = 68)b Total (N = 222)
N0 117 (76%) 19 (28%) 136 (61%)
N1a 37 (24%) 49 (72%) 86 (39%)
pT3 3 (2%) 6 (9%) 9 (4%)
Grade 3 12 (8%) 36 (53%) 48 (22%)
Lympho-vascular invasion 7 (5%) 43 (63%) 50 (23%)
ER <50% and PgR < 50% – 1 (1%) 1 (0%)
Ki67 > 30% 10 (6%) 19 (28%) 29 (13%)
Risk factors, mean (range) 0.2 (0–1) 1.6 (1–3) 0.6 (0–3)
Data are n (%) unless otherwise indicated
aDefinitions. Low-risk: N0 and ≤1 predefined risk factor, or N1a with no predefined risk factor. Non-low-risk: N0 and ≥2 predefined risk factors, or N1a with ≥1 predefined
risk factors (Comment: These classifications were fixed in the protocol but not disclosed to study participants)
bOne evaluable patient withdrew from the study before the second tumor board provided a recommendation
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Patient characteristics of all 229 patients entered
into the study are shown in Table 1. Median patient
age was 58 years (range 32 to 82). Two thirds of the
patients were postmenopausal, pT-stage was mostly
T1b, T1c or T2, 21% of the patients had grade 3 tu-
mors and 22% had peritumoral lympho-vascular inva-
sion. A total of 88 (38%) of all patients had 1–3
positive nodes. Histologic type was mostly invasive
ductal carcinoma. Risk factors and their distribution
among risk groups for the evaluable patients are
shown in Table 2. The distribution of ODX low-, inter-
mediate-, and high-risk RS was 65% (100 of 154), 31% (48
of 154), and 4% (6 of 154) in the low-risk group and 51%
(34 of 67), 28% (19 of 67), and 21% (14 of 67) in the non-
low-risk group, respectively.
In the 222 patients evaluable for the primary end-
point, the recommendations of the first and second
tumor board differed in 45 (20%) patients: 23 of 154
(15%, 95% CI 10–22%) in the low-risk group, and 22
of 68 (32%, 95% CI 22–45%) in the non-low-risk
group (Fig. 2). Therefore, in both groups the null
hypothesis (5% change in the low risk, 10% change in
the non-low risk group) was rejected at the 0.025
level. The p-value was <0.001 in both groups.
Specifically, in the low-risk group, five of 113 (4%,
95% CI 1–10%) patients with an initial HT
recommendation were changed to CT + HT, while 18
of 41 (44%, 95% CI 28–60%) of patients with an ini-
tial CT + HT recommendation were changed to HT.
In the non-low-risk group, three of 19 (16%, 95% CI
3–40%) patients were changed from HT to CT + HT,
while 19 of 48 (40%, 95% CI 26–55%) were changed
from CH + HT to HT.
Characteristics of the 8 patients with a change in
recommendation from HT to CT + HT can be found
in the Appendix (Table 7). Most notably for these 8
patients the median RS (range) was 30 (18–51),
showing that RS was a very prominent factor for
these 8 decision changes, since half the patients were
in the high and the other half in the intermediate
risk RS group.
We also investigated how the recommendations of
the tumor boards translated into actual patient care.
The “evolution” of treatment recommendations from
the first tumor board recommendation to the treat-
ment actually given is shown in Table 3. In addition,
we have analyzed the reasons for decision changes in
the low-risk/non-low-risk groups (Table 4): Most
treatment decision changes were due to the know-
ledge of RS at the second tumor board (Table 4).
Recommendations of the second tumor board that
included knowledge of RS are shown in Table 5. All
patients with a high-risk RS (31–100) were recom-
mended to receive CT + HT. Most (124 of 134; 93%)
but not all of the patients with a low RS (0–17) were
offered HT only. In the patients with intermediate RS
(18–30) tumor board recommendations were variable.
Treatment recommendations changed in 22% of pa-
tients with RS 0–17; 16% of patients with RS 18–30;
and 20% of patients with RS 31–100.
Fig. 2 Primary endpoint: Change in adjuvant treatment recommendation between the first and second tumor board (after knowledge of the ODX
recurrence score)
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The distribution of RS overall as well as for different
subgroups can be found in Table 6. A graphic presenta-
tion of all the recurrence scores is shown in Fig. 3.
Discussion
In this multicenter, prospective cohort study of early
breast cancer patients we studied how Swiss tumor
boards made use of the ODX 21-gene multigene
expression assay RS. This assay may be considered for
routine use in the USA for all patients with ER-positive/
HER2-negative tumors of at least 5 mm diameter (T1b
and larger) [26]. Our findings suggest that this assay
may be used in a more judicious manner, as opposed to
testing all patients with early stage ER-positive/HER2-
negative breast cancer. We found that knowledge of the
RS resulted in a very low rate of decision change for pa-
tients initially offered HT only, i.e. 5 of 113 (4%, 95% CI
1–10%) in the low-risk group, and 3 of 19 (16%, 95% CI
3–40%) in the non-low-risk group. We therefore think
that it is reasonable for these patients to forgo additional
testing with the ODX assay, particularly for the patients
fulfilling the low-risk criteria (Table 2). Obviously, this
statement has to be tempered by the fact that the
confidence intervals are large, and that the primary deci-
sion to recommend HT only is subjective and may not
be applicable to other centers. On the other hand, pa-
tients initially considered for CT + HT have a high like-
lihood of decision change based on the knowledge of the
RS, with 18 of 41 (44%) in the low-risk and 19 of 48
(40%) in the non-low-risk group. These patients at non
low-risk as defined by our criteria may be considered
good candidates to have ODX testing.
Overall, our data show that the ODX assay, when
readily available, significantly impacts adjuvant treatment
decisions in patients with ER-positive/HER2-negative
early breast cancer. Changes in treatment recommenda-
tions at the second tumor board were predominantly
driven by the availability of the RS. When considering
the entire study population treatment decisions chan-
ged in approximately 20% of patients, which is some-
what lower than the level of change seen in other
studies [9, 11–18]. A recent meta-analysis of 15
Table 3 Evolution of treatment recommendations
Risk category Low-risk group
(N = 154)
Non-low-risk group
(N = 67)
Recommendation, n CT + HT HT CT + HT HT
1st tumor board 41 (27%) 113 (73%) 48 (72%) 19 (28%)
1st shared decision 40 (26%) 114 (74%) 47 (70%) 20 (30%)
Add knowledge of recurrence score
2nd tumor board 28 (18%) 126 (82%) 32 (48%) 35 (52%)
2nd shared decision 24 (16%) 130 (84%) 32 (48%) 35 (52%)
Treatment actually given 23 (15%) 130 (84%) 28 (42%) 37 (55%)
CT chemotherapy, HT endocrine therapy
Table 4 Reason for change of recommendation
Low-risk group
(N = 154)
Non-low-risk group
(N = 67)
Number of patients with
decision change, n
23 22
Reasonsa for decision
change, n:
Recurrence score 23 (100%) 21 (95%)
Opinion of tumor
board changed
1 (4%) 1 (5%)
Patient preference 3 (13%) 1 (5%)
Other 2 (9%) 1 (5%)
aMore than one reason for changing the treatment decision were possible
Further factors analyzed and never found to be a reason for change of
recommendation after second tumor board were: Tumor board composition
change, new medical information
Table 5 Distribution of second tumor board recommendations
according to the recurrence score
Risk category Low-risk
group (N = 154)
Non-low-risk
group (N = 67)
Total
CT + HT HT CT + HT HT
All recommendations 28 126 32 35 221
RS 0–17 (low) 4 96 6 28 134 (61%)
RS 18–30 (intermediate) 18 30 12 7 67 (30%)
RS 31–100 (high) 6 0 14 0 20 (9%)
Table 6 Distribution of RS overall and for different subgroups
Variable RS median (range)
All patients, N = 222 16 (0–68)
Tumor grade (BRE)
G1, N = 28 14 (6–28)
G2, N = 146 15 (0–51)
G3, N = 48 24 (5–68)
pN stage
pN0, N = 136 17 (0–68)
pN1a, N = 86 14 (0–51)
Peritumoral lympho-vascular invasion
No, N = 172 16 (0–68)
Yes, N = 50 15 (2–44)
Invasive tumor size
≤ 2 cm, N = 133 15 (0–43)
> 2 cm, N = 89 16 (0–68)
Ki67
≤ 30, N = 193 15 (0–51)
> 30, N = 29 24 (1–68)
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studies that investigated the impact of the ODX assay on
adjuvant treatment decisions reported that the additional
information provided by the RS changed the recommen-
dation for adjuvant treatment in 30% of cases [30]. The
lower rate of decision changes in our study may reflect the
fact that the assay was not applied to all patients who sat-
isfied the inclusion criteria. Investigators were free not to
offer study participation to patients. Investigators were
also free in their interpretation of the RS which leaves
ambiguity particularly in the intermediate-risk group (RS
18–30).The observation that the majority of treatment de-
cision changes resulted in a de-escalation of chemo-
endocrine therapy to adjuvant endocrine therapy alone is
consistent with other studies. Overall, the proportion of
patients for whom chemotherapy was recommended was
reduced from 40.3% (89/221) at the first tumor board to
27.1% (60/221) at the second tumor board (a 13.2% net re-
duction). These data are similar to the findings of the
meta analysis from Augustovski et al. [30] and a pooled
analysis of four studies by Albanell et al. [31] which re-
ported net reductions in recommendations for chemo-
therapy of 12% and 13.5%, respectively. In a recent large
population-based cohort study of almost 1000 patients
from Ontario (Canada) ODX-testing changed the oncolo-
gists’ recommendations in half the patients. However this
study included a pretest category of “unsure” (whether
chemotherapy should be given) which accounted for 328
of 508 patients (65%) who had a change in recommenda-
tion. This large study confirms that ODX is far more likely
to change the recommendation to omitting chemotherapy
(38%) than to recommending it (15%) [32].
Our data are also in agreement with recent recom-
mendations from the 14th St Gallen International Breast
Cancer Conference [33]. These guidelines support omit-
ting adjuvant chemotherapy in patients with a low prob-
ability of recurrence as determined by multigene
expression profiling techniques. At the same time these
guidelines caution that adjuvant chemotherapy may be
justified in patients with poor pathologic features even if
they have a favorable multigene assay result.
Other multi-gene tests and the standardized
immunohistochemistry-based scoring system IHC 4 have
also been useful in particular to divide patients at inter-
mediate risk for relapse into groups at higher risk and at
lower risk [34]. One study suggests that the amount of
prognostic information contained in four widely per-
formed immunohistochemical (IHC) assays is similar to
that in a multi-gene test [35]. Moreover a study compar-
ing several multi-gene tests to IHC4 (using semiquanti-
tative assessment) showed that the IHC4 score provides
better prognostic information than the corresponding
quantitative RNA measurements [36]. Thus the combin-
ation of quality controlled conventional IHC tests and
multigene signatures may provide more information for
some patients at intermediate risk of relapse.
Our study has strengths and limitations. Strengths in-
clude the prospective nature of the study, prospectively
defined endpoints, hypotheses and sample size planning,
the formal requirement of the presence of the pathologist
at the multidisciplinary tumor-board, the documentation
of the multi-step decision-making and implementation
process and the trial sponsoring by an academic group
(SAKK). On the other hand, observational studies have
well-known limitations. When planned prospectively,
studies are subject to selection bias. In observational stud-
ies investigators will influence study results when they are
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subject of the investigation and if they are not blinded for
the study endpoints and study goals. Furthermore, unob-
servable and unobserved factors not included in the ana-
lyses, are likely to play a role in the patterns and results
observed.
Conclusion
In conclusion, we suggest that patients given a recom-
mendation of HT by a Swiss tumor board may forgo
ODX testing, especially if categorized as low risk by the
criteria listed in the legend of Table 2. By contrast, in pa-
tients recommended CT + HT, knowledge of RS had
considerable potential to change treatment recommen-
dations in both risk groups of our patients.
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